Related Experiment Video
Updated: Aug 16, 2026
03:40
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Intranasal Azelastine for Recurrent Acute Rhinosinusitis Prophylaxis: A Multicenter Retrospective Study
Akshay R Prabhakar1, Justina R Varghese1, William Marshall2
1Department of Otolaryngology-Head and Neck Surgery, Houston Methodist Hospital, Houston, Texas, USA.
International Forum of Allergy & Rhinology
|August 14, 2026
Summary
Azelastine significantly reduced recurrent acute rhinosinusitis (RARS) episodes by 56.6% in a self-controlled analysis. These findings support further investigation of azelastine for managing RARS.
Area of Science:
- Otolaryngology
- Pharmacology
Background:
- Recurrent acute rhinosinusitis (RARS) poses a significant burden on patients.
- Effective treatment options for RARS are continuously being sought.
Purpose of the Study:
- To evaluate the efficacy of azelastine in reducing episodes of RARS.
- To assess treatment consistency across patient subgroups.
Main Methods:
- A self-controlled analysis was employed to assess treatment outcomes.
- Data were analyzed for patients with RARS, including those using intranasal corticosteroids (ICS) and those with chronic rhinosinusitis (CRS).
Main Results:
- Mean RARS episodes decreased from 2.72 to 1.18 per year, a 56.6% reduction.
- The treatment effect of azelastine was consistent across various patient subgroups.
Conclusions:
- Azelastine demonstrates significant efficacy in reducing RARS episodes.
- Findings support azelastine as a potential therapeutic agent for RARS.
- Further evaluation via prospective randomized controlled trials is warranted.
